Retatrutide: The Triple-Agonist GLP-1 That Could Change Everything

28.7% Body Weight Loss in Phase 3

That number isn't a typo. In December 2025, Eli Lilly released topline results from TRIUMPH-4 — the first completed Phase 3 trial for retatrutide. Participants on the 12 mg dose lost an average of 28.7% of their body weight over 68 weeks. That translates to roughly 71 pounds.

For context, tirzepatide (Mounjaro/Zepbound) topped out at about 22.5% in its pivotal SURMOUNT-1 trial. Semaglutide (Wegovy) hit around 15% in STEP 1. Retatrutide's Phase 3 result is the largest average weight loss ever reported in an obesity drug trial.

So what makes this molecule different?

Three Receptors Instead of One or Two

If you've been following GLP-1 medications, you already know the basic framework. Semaglutide activates one receptor: GLP-1. Tirzepatide activates two: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and the glucagon receptor.

Each receptor does something distinct.

GLP-1 slows gastric emptying, signals satiety to the brain, and improves insulin sensitivity. This is the mechanism that semaglutide, tirzepatide, and retatrutide all share.

GIP (glucose-dependent insulinotropic polypeptide) amplifies insulin secretion, influences fat metabolism, and appears to enhance the appetite-suppressing effects of GLP-1 when both receptors are activated together. This is the second lever tirzepatide pulls — and why it outperforms semaglutide in head-to-head trials.

Glucagon is the third lever, and it's the one that makes retatrutide genuinely new. Glucagon is typically thought of as the "opposite" of insulin: it raises blood sugar by telling the liver to release stored glucose. But glucagon receptors also regulate energy expenditure, fat oxidation, and lipid metabolism in ways that go beyond blood sugar control.

When you activate glucagon receptors alongside GLP-1 and GIP, you get something no approved drug currently provides — increased energy expenditure even at rest, accelerated breakdown of stored fat (lipolysis), and dramatic reductions in liver fat. The body burns more calories while also eating less. That combination drives the outsized weight loss numbers.

Phase 2 Results Set the Stage

Before the Phase 3 data, a Phase 2 trial published in the New England Journal of Medicine in 2023 gave the first clear signal that retatrutide was something special.

At the highest dose (12 mg), participants with obesity lost an average of 24.2% of their body weight over 48 weeks. At lower doses (8 mg), the average was still 22.8%. Even the 4 mg dose produced 17.5% weight loss — roughly comparable to the best results from approved GLP-1 medications.

The liver data was arguably even more striking. Participants with fatty liver disease showed mean liver fat reductions of up to 82.4% at 24 weeks on the 12 mg dose. Up to 86% of participants on the highest dose achieved normal liver fat levels. No approved medication comes close to that kind of liver fat reduction.

TRIUMPH Phase 3 Program: What We Know So Far

Eli Lilly's Phase 3 program for retatrutide is called TRIUMPH. It includes four main studies evaluating retatrutide across more than 5,800 participants:

• TRIUMPH-1 and TRIUMPH-2 — Weight management basket trials with protocols for obstructive sleep apnea (OSA) and osteoarthritis (OA) nested within
• TRIUMPH-3 — Weight management in people with existing cardiovascular disease
• TRIUMPH-4 — A standalone knee osteoarthritis trial (the first to report results)

TRIUMPH-4 tested retatrutide at 9 mg and 12 mg doses over 68 weeks in people with obesity and knee osteoarthritis. The headline numbers:

• 12 mg dose: 28.7% mean body weight loss (about 71.2 lbs), with WOMAC knee pain scores improving by 3.7 points vs. 2.1 for placebo
• 9 mg dose: 26.4% mean body weight loss, with pain scores improving by 4.0 points
• Placebo: 4.6% body weight loss

Seven additional Phase 3 readouts are expected throughout 2026. These will include data on a 4 mg maintenance dose, cardiovascular outcomes, sleep apnea, and the core weight management indications. The full data package will be much larger than what we have now.

Side Effects: Familiar Territory With One New Wrinkle

The gastrointestinal side effects look a lot like what you'd expect from any incretin-based drug. In TRIUMPH-4:

• Nausea: 38.1% at 9 mg, 43% at 12 mg (vs. 10% placebo)
• Diarrhea and constipation were common across both dose groups
• Vomiting and decreased appetite also occurred more frequently than placebo
• Discontinuation rates: 12.2% at 9 mg, 18.2% at 12 mg (vs. 4% placebo)

These numbers are comparable to — or slightly higher than — what tirzepatide showed in SURMOUNT trials, which makes sense given the added glucagon component putting extra metabolic stress on the GI system.

The new finding to watch is dysesthesia — an abnormal skin sensation (tingling, numbness, or a "pins and needles" feeling). It showed up in 8.8% of the 9 mg group and 20.9% of the 12 mg group, compared to just 0.7% on placebo. These episodes were mostly mild and rarely led to anyone dropping out, but it's a signal the FDA will scrutinize. Analysts are waiting for more detailed characterization from the remaining TRIUMPH trials before drawing firm conclusions.

Retatrutide vs Tirzepatide vs Semaglutide

Here's how the three stack up based on their best available clinical trial data:

	Semaglutide 2.4 mg	Tirzepatide 15 mg	Retatrutide 12 mg
Mechanism	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Best trial weight loss	~15% (STEP 1, 68 wks)	~22.5% (SURMOUNT-1, 72 wks)	~28.7% (TRIUMPH-4, 68 wks)
Head-to-head	Lost to tirzepatide in SURMOUNT-5	Beat semaglutide in SURMOUNT-5	No head-to-head yet
Liver fat reduction	Modest	Moderate	Up to 82-86% normalization
FDA status	Approved (Wegovy)	Approved (Zepbound)	Phase 3 trials
Availability	Now	Now	Projected 2027-2028

A couple of important caveats. The retatrutide numbers come from a trial in people with both obesity and osteoarthritis — a specific population that may respond differently than the general obesity population. Direct head-to-head trials against tirzepatide and semaglutide haven't happened yet. Cross-trial comparisons are useful for ballpark estimates, but they're not definitive.

If you're currently exploring semaglutide vs tirzepatide, those remain the two FDA-approved options right now. Retatrutide is the next chapter, not the current one.

Why the Glucagon Component Matters Beyond Weight Loss

The glucagon receptor activity in retatrutide does more than just increase calorie burn. Preclinical and early clinical data suggest several metabolic effects:

Liver fat clearance. Glucagon receptor activation drives hepatic lipid oxidation — it tells the liver to burn its stored fat. The Phase 2 liver data (up to 86% of participants normalizing liver fat) is relevant for the millions of people with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Lilly is running a dedicated trial for this indication.

Energy expenditure. Unlike GLP-1 agonists that primarily reduce calorie intake, glucagon activation appears to increase resting energy expenditure. Your body burns more even when you're not active. This may partly explain why retatrutide's weight loss exceeds what appetite reduction alone would predict.

Fat mobilization. Glucagon decreases lipogenesis (new fat creation) and increases lipolysis (fat breakdown), raising circulating free fatty acids that the body can then use as fuel.

The flip side: glucagon can raise blood sugar. In a drug designed for people with type 2 diabetes, that's a concern. Phase 2 data in diabetic populations showed retatrutide still improved glycemic control, likely because the GLP-1 and GIP components offset the glucagon-driven glucose release. But the balance is delicate, and the diabetes-specific TRIUMPH data will be critical.

When Could Retatrutide Get FDA Approval?

Based on publicly available information:

• Late 2026: Eli Lilly is expected to have enough data from the TRIUMPH program to compile a full NDA (New Drug Application) submission
• Early-to-mid 2027: Likely NDA filing with the FDA
• Late 2027 to early 2028: Potential FDA approval under standard review timelines (6-10 months)

This assumes no unexpected safety signals from the remaining trials and no major regulatory delays. Lilly has been executing quickly — they have extensive experience from the tirzepatide approval process — but timelines can always shift.

Will Retatrutide Be Available Through Telehealth?

Once FDA-approved, retatrutide will likely follow the same distribution path as tirzepatide (Zepbound). Eli Lilly already sells Zepbound directly through LillyDirect and has partnered with telehealth platforms. There's no reason to expect they'd take a different approach with retatrutide.

Some compounding pharmacies and telehealth clinics have begun offering retatrutide prescriptions in early 2026, typically at $300-600 per month. The legal footing here is uncertain because retatrutide isn't FDA-approved — compounding laws are designed for approved drugs during shortages, not unapproved investigational molecules. Supply interruptions have already happened at some clinics.

The safer play is to wait for FDA approval and access it through legitimate channels. If you're looking for weight loss support right now, talking with a licensed provider about currently approved options like tirzepatide or semaglutide is the more straightforward path.

Who Might Benefit Most From Retatrutide?

Based on the trial data and mechanism of action, a few groups stand out:

People who've plateaued on current GLP-1 medications. If semaglutide or tirzepatide produced initial weight loss that stalled well short of your goals, the additional glucagon pathway might push past that plateau. This is speculation — there's no switching trial yet — but the pharmacology supports the logic.

People with significant fatty liver disease. The liver fat data is the most striking differentiator. No approved weight loss drug produces the degree of liver fat clearance seen with retatrutide. For people with MASLD who need aggressive intervention, this could be a meaningful advantage.

People with higher BMIs who need more than 20% weight loss. When GLP-1 medications max out at 15-22%, there's a ceiling that still leaves many patients well above healthy weight ranges. Retatrutide's average of 28.7% brings a larger percentage of participants closer to clinically meaningful endpoints.

People with obesity-related osteoarthritis or sleep apnea. Lilly is specifically studying these co-conditions. The TRIUMPH-4 data already shows meaningful pain reduction alongside weight loss. If the OSA data is similarly strong, retatrutide may get dual indications.

What to Do While You Wait

Retatrutide isn't available yet through normal medical channels, and it may not be until 2028. That's not wasted time. Here's how to make the most of it:

If you haven't started any GLP-1 medication yet, take the provider matching quiz to connect with a clinician who can evaluate you for currently approved options. Starting semaglutide or tirzepatide now gives you a head start — and if retatrutide eventually proves superior, switching is always possible.

If you're already on a GLP-1 and doing well, keep going. Don't stop a working medication to wait for something that might be available in two years. When retatrutide launches, your provider can discuss whether the additional glucagon mechanism offers enough upside to justify a change.

If cost is a barrier, read the peptide therapy cost guide and explore options. The pricing environment has shifted significantly in 2026 with oral Wegovy, Medicare coverage for Zepbound, and Lilly's direct-to-consumer pricing.

If you're interested in other peptide therapies for goals beyond weight loss — like recovery, sleep, or performance — peptides such as BPC-157 and CJC-1295/Ipamorelin work through entirely different mechanisms and can be explored independently.

Retatrutide FAQs

Is retatrutide FDA-approved?

No. As of April 2026, retatrutide has not been submitted for FDA approval and remains an investigational drug. The first Phase 3 results (TRIUMPH-4) were reported in December 2025, with seven additional Phase 3 readouts expected in 2026. Eli Lilly is projected to file a New Drug Application in early-to-mid 2027, with potential approval in late 2027 or early 2028. You cannot legally obtain retatrutide through standard prescription channels right now — it's only available through clinical trials and a small number of compounding sources with uncertain legal standing.

How does retatrutide compare to tirzepatide and semaglutide for weight loss?

In cross-trial comparisons, retatrutide has produced the highest average weight loss of any obesity drug studied: 28.7% at the 12 mg dose over 68 weeks. Tirzepatide achieved about 22.5% at its highest dose over 72 weeks, and semaglutide reached about 15% over 68 weeks. The key difference is mechanism: retatrutide adds glucagon receptor activation to the GLP-1 and GIP pathways, increasing energy expenditure and fat oxidation on top of appetite suppression. No direct head-to-head trial between retatrutide and the other two exists yet.

What is a triple-agonist GLP-1 medication?

A triple agonist activates three different hormone receptors with a single molecule. In retatrutide's case, those are the GLP-1 receptor (appetite and blood sugar), the GIP receptor (fat metabolism and insulin), and the glucagon receptor (energy expenditure and liver fat clearance). Semaglutide is a single agonist (GLP-1 only). Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide is the first triple agonist to reach Phase 3 trials for obesity. The added glucagon component is what separates it from everything currently on the market.

What are retatrutide's side effects?

The most common side effects are gastrointestinal: nausea (38-43%), diarrhea, constipation, vomiting, and decreased appetite. These are similar to the side effect profiles of semaglutide and tirzepatide. A new finding specific to retatrutide is dysesthesia — abnormal skin sensations like tingling or numbness — which appeared in about 21% of participants on the highest dose. Most cases were mild. Discontinuation rates in TRIUMPH-4 were 12-18% depending on dose, compared to 4% for placebo. The full safety profile will become clearer as additional Phase 3 results are released throughout 2026.

Will retatrutide be available through telehealth providers?

Once FDA-approved, retatrutide will almost certainly be prescribed through telehealth platforms, just as tirzepatide and semaglutide already are. Eli Lilly sells Zepbound through LillyDirect and partners with multiple telehealth companies. Some clinics are currently offering compounded retatrutide off-label, but the legal status is murky and supply is unreliable. If you're looking for weight loss treatment now, finding a qualified provider to discuss approved options is the more reliable approach.

What is retatrutide's development code name?

Retatrutide's development code is LY3437943. You may see it referred to this way in clinical trial databases, research papers, and on sites like ClinicalTrials.gov. Eli Lilly has not yet announced a brand name — that typically comes closer to FDA submission or approval.